动物造模,2型糖尿病 z-bio 2022-07-26 298

　　Objective: To explore the effectiveness and feasibility of vaccine immune intervention against insulin resistance targeting human RBP-4, and to provide basic research data for the advancement of new treatment methods for type 2 diabetes.

　　Methods: Type 2 diabetic mice were subcutaneously immunized with a vaccine expressing human RBP-4 using T7 phage as a vector, and an empty vector group and a blank control group were set at the same time. The animals were sacrificed at 20 weeks for pathological examination.

　　RESULTS: RBP-4 vaccine effectively induced the production of anti-RBP-4 IgG antibody, and reached the peak at 12 weeks. At the same time, the fasting blood glucose level of the immunized group gradually decreased from the 8th week, and at the 12th week, it was higher than that of the empty vector group. It was significantly different from the blank group, and always maintained below the incidence value of type 2 diabetes (7 mmol/L). During the experiment, the type 2 diabetic mice did not have obvious abnormalities such as curling up, prickly hair, scratching the nose, convulsions, etc. No obvious lesions were observed in the heart, liver, spleen, lung, and kidney tissues of the mice in the immune group and the empty vector group, indicating that RBP -4 The vaccine is safe.

　　Conclusion: RBP-4 vaccine can significantly reduce blood glucose in type 2 diabetic mice, which may become a new breakthrough in the treatment of insulin resistance.